SHR-A2102 / Jiangsu Hengrui Pharma 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
16 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
SHR-A2102 / Jiangsu Hengrui Pharma
NCT06738251: A Phase III Study of SHR-A2102 Versus Investigator-selected Therapy in Advanced Urothelial Carcinoma

Recruiting
3
402
RoW
SHR-A2102 for Injection, Docetaxel Injection, Paclitaxel Injection, Gemcitabine Hydrochloride for Injection, Pemetrexed Disodium for Injection
Shanghai Hengrui Pharmaceutical Co., Ltd.
Advanced Urothelial Carcinoma
07/26
09/27
NCT06879145: Clinical Study on the Treatment of MIBC Patients With SHR-A2102 Injection Combined With Adebrelimab (SHR-1316)

Not yet recruiting
2/3
840
RoW
SHR-A2102；Adebrelimab
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Muscular Invasive Bladder Cancer (MIBC)
12/31
12/31
NCT06547736: Exploratory Platform Research on Precision Therapy of Advanced Pancreatic Cancer

Not yet recruiting
2
120
RoW
SHR-A2102 or/and HRS-4642, SHR-A1904 or/and HRS-4642, SHR-A1811 or/and HRS-4642
Fudan University, Jiangsu HengRui Medicine Co., Ltd.
Pancreatic Cancer
03/27
06/27
NCT06649331: Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer

Recruiting
2
120
RoW
SHR-A1811, SHR-A1921, SHR-A2009, SHR-A2102
Fudan University
Advanced Breast Cancer, Metastatic Breast Cancer, Triple Negative Breast Cancer (TNBC), HER2-negative Breast Cancer, Breast Cancer
09/26
09/27
SHR-A2102-208, NCT06654440: A Trial of SHR-A2102 for Treatment of Advanced Gynecological Malignancy

Recruiting
2
100
RoW
SHR-A2102 for injection
Shanghai Hengrui Pharmaceutical Co., Ltd.
Advanced Gynecological Malignancy
08/25
10/26
NCT06819319: SHR-A2102 Combined with Adebrelimab As Neoadjuvant Therapy for Early Triple-Negative Breast Cancer

Not yet recruiting
2
52
NA
SHR-A2102 ; Adebrelimab injection
Henan Cancer Hospital
TNBC - Triple-Negative Breast Cancer
12/26
12/30
NCT06895928: A Trial of SHR-A2102 With Other Antitumor Therapies in Advanced Solid Tumors

Not yet recruiting
2
400
RoW
SHR-A2102, Bevacizumab Injection, Adebelimab Injection, Ametinib Mesylate Tablets, Osimertinib Mesylate Tablets
Shanghai Hengrui Pharmaceutical Co., Ltd.
Advanced Solid Tumors
12/28
12/28
BCTOP-L-M05, NCT05594095: SNF Platform Study of HR+/ HER2-advanced Breast Cancer

Recruiting
2
620
RoW
PIK3CA inhibitor, AKT inhibitor, Carrelizumab, SHR1210, Famitinib, Fluzoparib, SHR3162, Dalpiciclib, SHR6390, SHR-A1811, Everolimus, Aromatase Inhibitors or Fulvestrant, Goserelin, TPC, Sorafenib, Apatinib, SHR-A1921, SHR-A2102, SHR-A2009, SHR-1167, SHR-6209, bevacizumab
Fudan University, Peking University Cancer Hospital & Institute, First Hospital of China Medical University, Sun Yat-sen University, First Affiliated Hospital Xi'an Jiaotong University, Chongqing University Cancer Hospital, Northern Jiangsu People's Hospital, Fujian Medical University Union Hospital, Ningbo Medical Center Lihuili Hospital, Shanghai First Maternity and Infant Hospital, Shanghai 6th People's Hospital, Affiliated Hospital of Nantong University, Nanchang People's Hospital, Liaoning Cancer Hospital & Institute, The Affiliated Hospital of Nantong University, The First Hospital of Jilin University
Breast Neoplasm, Breast Cancer, Hormone Receptor Positive Tumor, HER2-negative Breast Cancer, Advanced Breast Cancer
12/25
12/26
ChiCTR2500097344: An exploratory trial of SHR-A2102 in combination with Adebrelimab for the treatment of unresectable stage III non-small cell lung cancer

Not yet recruiting
2
20
 
Adebrelimab combined with SHR-A2102
Shanghai Chest Hospital; Shanghai Chest Hospital, Self-raised
Stage III unresectable non-small cell lung cancer
 
 
SHR-A2102-201, NCT06417554: A Trial of SHR-A2102 With or Without Antitumor Therapy in Advanced Solid Tumors

Recruiting
1/2
80
RoW
SHR-A2102, SHR-A2102 ; Adebrelimab injection
Shanghai Hengrui Pharmaceutical Co., Ltd.
Advanced Solid Tumors
07/27
07/27
SHR-A2102-203, NCT06474468: A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Esophageal Cancer

Recruiting
1/2
148
RoW
SHR-A2102；Adebrelimab；Cisplatin
Shanghai Hengrui Pharmaceutical Co., Ltd.
Advanced or Metastatic Esophageal Cancer
10/26
10/26
NCT06512051: A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-small Cell Lung Cancer

Recruiting
1/2
248
RoW
SHR-A2102；Adebrelimab；Cisplatin/ Carboplatin
Shanghai Hengrui Pharmaceutical Co., Ltd.
Advanced or Metastatic Non-small Cell Lung Cancer
10/26
10/26
NCT06589778: A Study of SHR-A2102 in Combination With Adebrelimab and SHR-8068 in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Recruiting
1/2
124
RoW
SHR-A2102, Adebelimab (SHR-1316), SHR-8068
Shanghai Hengrui Pharmaceutical Co., Ltd.
Non-Small Cell Lung Cancer
04/26
04/26
NCT06639347: A Trial of SHR-A2102 With Antitumor Therapy in Advanced Urothelial Carcinoma

Recruiting
1/2
90
RoW
SHR-A2102, Adebrelimab injection, SHR-8068 injection
Shanghai Hengrui Pharmaceutical Co., Ltd.
Advanced Urothelial Carcinoma
05/27
05/27
SHR-A2102-I-101, NCT05735275: A Phase 1 Study of SHR-A2102 in Subjects With Advanced Solid Tumors.

Recruiting
1
252
RoW
SHR-A2102
Shanghai Hengrui Pharmaceutical Co., Ltd.
Advanced Or Metastatic Solid Tumor Malignancies
08/25
08/25
SHR-A2102-I-102, NCT05701709: Phase I Study of SHR-A2102 in Patients With Advanced Solid Tumors

Active, not recruiting
1
395
RoW
SHR-A2102
Shanghai Hengrui Pharmaceutical Co., Ltd.
Advanced Solid Tumors
08/25
08/25
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
SHR-A2102 / Jiangsu Hengrui Pharma
NCT06738251: A Phase III Study of SHR-A2102 Versus Investigator-selected Therapy in Advanced Urothelial Carcinoma

Recruiting
3
402
RoW
SHR-A2102 for Injection, Docetaxel Injection, Paclitaxel Injection, Gemcitabine Hydrochloride for Injection, Pemetrexed Disodium for Injection
Shanghai Hengrui Pharmaceutical Co., Ltd.
Advanced Urothelial Carcinoma
07/26
09/27
NCT06879145: Clinical Study on the Treatment of MIBC Patients With SHR-A2102 Injection Combined With Adebrelimab (SHR-1316)

Not yet recruiting
2/3
840
RoW
SHR-A2102；Adebrelimab
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Muscular Invasive Bladder Cancer (MIBC)
12/31
12/31
NCT06547736: Exploratory Platform Research on Precision Therapy of Advanced Pancreatic Cancer

Not yet recruiting
2
120
RoW
SHR-A2102 or/and HRS-4642, SHR-A1904 or/and HRS-4642, SHR-A1811 or/and HRS-4642
Fudan University, Jiangsu HengRui Medicine Co., Ltd.
Pancreatic Cancer
03/27
06/27
NCT06649331: Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer

Recruiting
2
120
RoW
SHR-A1811, SHR-A1921, SHR-A2009, SHR-A2102
Fudan University
Advanced Breast Cancer, Metastatic Breast Cancer, Triple Negative Breast Cancer (TNBC), HER2-negative Breast Cancer, Breast Cancer
09/26
09/27
SHR-A2102-208, NCT06654440: A Trial of SHR-A2102 for Treatment of Advanced Gynecological Malignancy

Recruiting
2
100
RoW
SHR-A2102 for injection
Shanghai Hengrui Pharmaceutical Co., Ltd.
Advanced Gynecological Malignancy
08/25
10/26
NCT06819319: SHR-A2102 Combined with Adebrelimab As Neoadjuvant Therapy for Early Triple-Negative Breast Cancer

Not yet recruiting
2
52
NA
SHR-A2102 ; Adebrelimab injection
Henan Cancer Hospital
TNBC - Triple-Negative Breast Cancer
12/26
12/30
NCT06895928: A Trial of SHR-A2102 With Other Antitumor Therapies in Advanced Solid Tumors

Not yet recruiting
2
400
RoW
SHR-A2102, Bevacizumab Injection, Adebelimab Injection, Ametinib Mesylate Tablets, Osimertinib Mesylate Tablets
Shanghai Hengrui Pharmaceutical Co., Ltd.
Advanced Solid Tumors
12/28
12/28
BCTOP-L-M05, NCT05594095: SNF Platform Study of HR+/ HER2-advanced Breast Cancer

Recruiting
2
620
RoW
PIK3CA inhibitor, AKT inhibitor, Carrelizumab, SHR1210, Famitinib, Fluzoparib, SHR3162, Dalpiciclib, SHR6390, SHR-A1811, Everolimus, Aromatase Inhibitors or Fulvestrant, Goserelin, TPC, Sorafenib, Apatinib, SHR-A1921, SHR-A2102, SHR-A2009, SHR-1167, SHR-6209, bevacizumab
Fudan University, Peking University Cancer Hospital & Institute, First Hospital of China Medical University, Sun Yat-sen University, First Affiliated Hospital Xi'an Jiaotong University, Chongqing University Cancer Hospital, Northern Jiangsu People's Hospital, Fujian Medical University Union Hospital, Ningbo Medical Center Lihuili Hospital, Shanghai First Maternity and Infant Hospital, Shanghai 6th People's Hospital, Affiliated Hospital of Nantong University, Nanchang People's Hospital, Liaoning Cancer Hospital & Institute, The Affiliated Hospital of Nantong University, The First Hospital of Jilin University
Breast Neoplasm, Breast Cancer, Hormone Receptor Positive Tumor, HER2-negative Breast Cancer, Advanced Breast Cancer
12/25
12/26
ChiCTR2500097344: An exploratory trial of SHR-A2102 in combination with Adebrelimab for the treatment of unresectable stage III non-small cell lung cancer

Not yet recruiting
2
20
 
Adebrelimab combined with SHR-A2102
Shanghai Chest Hospital; Shanghai Chest Hospital, Self-raised
Stage III unresectable non-small cell lung cancer
 
 
SHR-A2102-201, NCT06417554: A Trial of SHR-A2102 With or Without Antitumor Therapy in Advanced Solid Tumors

Recruiting
1/2
80
RoW
SHR-A2102, SHR-A2102 ; Adebrelimab injection
Shanghai Hengrui Pharmaceutical Co., Ltd.
Advanced Solid Tumors
07/27
07/27
SHR-A2102-203, NCT06474468: A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Esophageal Cancer

Recruiting
1/2
148
RoW
SHR-A2102；Adebrelimab；Cisplatin
Shanghai Hengrui Pharmaceutical Co., Ltd.
Advanced or Metastatic Esophageal Cancer
10/26
10/26
NCT06512051: A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-small Cell Lung Cancer

Recruiting
1/2
248
RoW
SHR-A2102；Adebrelimab；Cisplatin/ Carboplatin
Shanghai Hengrui Pharmaceutical Co., Ltd.
Advanced or Metastatic Non-small Cell Lung Cancer
10/26
10/26
NCT06589778: A Study of SHR-A2102 in Combination With Adebrelimab and SHR-8068 in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Recruiting
1/2
124
RoW
SHR-A2102, Adebelimab (SHR-1316), SHR-8068
Shanghai Hengrui Pharmaceutical Co., Ltd.
Non-Small Cell Lung Cancer
04/26
04/26
NCT06639347: A Trial of SHR-A2102 With Antitumor Therapy in Advanced Urothelial Carcinoma

Recruiting
1/2
90
RoW
SHR-A2102, Adebrelimab injection, SHR-8068 injection
Shanghai Hengrui Pharmaceutical Co., Ltd.
Advanced Urothelial Carcinoma
05/27
05/27
SHR-A2102-I-101, NCT05735275: A Phase 1 Study of SHR-A2102 in Subjects With Advanced Solid Tumors.

Recruiting
1
252
RoW
SHR-A2102
Shanghai Hengrui Pharmaceutical Co., Ltd.
Advanced Or Metastatic Solid Tumor Malignancies
08/25
08/25
SHR-A2102-I-102, NCT05701709: Phase I Study of SHR-A2102 in Patients With Advanced Solid Tumors

Active, not recruiting
1
395
RoW
SHR-A2102
Shanghai Hengrui Pharmaceutical Co., Ltd.
Advanced Solid Tumors
08/25
08/25

Download Options